PIKFYVE and neoplasm: Last, in order to better illustrate the anti-tumor activity of PIKfyve and tubulin dual-target inhibitor HZX-02-059, PIKfyve-specific inhibitor apilimod and tubulin-specific inhibitor vincristine were employed in this study to examine whether the combination would have a synergistic effect on DHL cells.